Imaging in Large Vessel Vasculitides

Bildgebende Diagnostik der Großgefäßvaskulitiden

Authors

Konstanze Guggenberger, Thorsten Bley

Affiliation

Department of Diagnostic and Interventional Radiology,
University-Hospital Würzburg, Germany

Key words

blood vessels, vascular, giant cell arteritis, Takayasu's arteritis,
large vessel vasculitis, MR angiography

received 15.11.2018

accepted 02.04.2019

Bibliography

DOI <https://doi.org/10.1055/a-0896-2833>

Published online: 16.5.2019

Fortschr Röntgenstr 2019; 191: 1083–1090

© Georg Thieme Verlag KG, Stuttgart · New York

ISSN 1438-9029

Correspondence

Dr. Konstanze Guggenberger
Department of Diagnostic and Interventional Radiology,
University-Hospital Würzburg, Oberdürrbacher Straße 6,
97080 Würzburg, Germany
Tel.: ++49/9 31/20 13 40 01
Guggenberg_K@ukw.de

ZUSAMMENFASSUNG

Hintergrund Unter dem Begriff Großgefäßvaskulitiden wird eine Gruppe primärer Vaskulitiden zusammengefasst, welche sich durch eine autoimmunologisch bedingte granulomatöse Entzündung mittelgroßer und großer Blutgefäße kennzeichnen und ein sehr variables klinisches, laborchemisches und radiologisches Erscheinungsbild aufweist. In den vergangenen Jahren haben bildgebende Verfahren zur Diagnostik und zum Monitoring von Großgefäßvaskulitiden an Bedeutung gewonnen. Mittels verschiedener bildgebender Verfahren lassen sich pathognomonische Veränderungen im Rahmen von Großgefäßvaskulitiden mit relativ hoher Sensitivität und mit relativ geringer Invasivität visualisieren.

Methode Diese Übersichtsarbeit stellt die wichtigsten bildgebenden Verfahren und einige typische Bildbefunde der beiden Hauptformen der Großgefäßvaskulitis – der Riesenzellarteriitis und der Takayasu-Arteriitis – vor, unter spezieller Berücksichtigung der jüngst veröffentlichten EULAR (The European League Against Rheumatism)-Empfehlungen über die Rolle der Bildgebung bei Patienten mit suspektierten Großgefäßvaskulitiden.

Ergebnisse und Schlussfolgerung Die farbkodierte Duplexsonografie, die Magnetresonanztomografie, die Computertomografie, die Positronenemissionstomografie und die diagnostische Subtraktionsangiografie sind die heutzutage gängigen bildgebenden Verfahren, die zur Diagnostik und zum Monitoring von Großgefäßvaskulitiden zum Einsatz kommen und eine sinnvolle, nicht- bzw. geringinvasive Alternative oder zumindest Zusatzdiagnostik zum bisherigen Goldstandard, der Temporalarterienbiopsie, darstellen. Die jüngsten EULAR-Leitlinien empfehlen die farbkodierte Duplexsonografie als Diagnostikum der ersten Wahl im Falle einer suspektierten Riesenzellarteriitis mit der Magnetresonanztomografie als gleichwertige Alternative im Falle uneindeutiger Befunde in der Sonografie und die Magnetresonanztomografie als bildgebendes Verfahren der ersten Wahl zur Detektion einer Takayasu-Arteriitis.

Kernaussagen:

- Die Bildgebung wird für die Diagnostik von Großgefäßvaskulitiden als erste, präferierte Ergänzung zur klinischen und laborchemischen Untersuchung empfohlen.
- Radiologische Verfahren sind für die Diagnostik einer Riesenzellarteriitis eine sinnvolle, nicht- bzw. geringinvasive Alternative/Ergänzung zur Temporalarterienbiopsie.
- Die jüngsten EULAR-Leitlinien empfehlen die farbkodierte Duplexsonografie als Diagnostikum der ersten Wahl im Falle einer suspektierten Riesenzellarteriitis mit der Magnetresonanztomografie als gleichwertige Alternative im Falle uneindeutiger Befunde in der Sonografie und die Magnetresonanztomografie als präferierte bildgebende Modalität zur Detektion einer Takayasu-Arteriitis.

ABSTRACT

Background Large vessel vasculitides comprise primary vasculitides of large and medium-sized arteries with various clinical, laboratory and radiological presentations. Imaging has become increasingly important in the diagnosis and monitoring of large vessel vasculitides. It complements clinical and laboratory examination and displays vasculitic changes of large extra- and intracranial arteries with relatively good diagnostic reliability and a low level of invasiveness.

Method This review presents the most important imaging modalities and some typical imaging findings in the context of the two main forms of large vessel vasculitis, giant cell arteritis and Takayasu's arteritis, with special regard to the recently launched EULAR (The European League Against Rheumatism)

recommendations on the role of imaging in patients with suspected large vessel vasculitides.

Results and Conclusion Color-coded duplex sonography (CCDS), magnetic resonance imaging (MRI), computed tomography (CT), and ^{18}F -fluorodeoxyglucose positron emission tomography are today's common imaging methods in large vessel vasculitides representing a reasonable and less invasive alternative or at least a good complement to temporal artery biopsy. Today's EULAR guidelines recommend an imaging test as the first complementary method to clinical examination with CCDS as the preferred diagnostic test in suspected giant cell arteritis, MRI as the equivalent alternative in the case of inconclusive results, and MRI as the first choice in suspected Takayasu's arteritis.

Key Points:

- Imaging is a noninvasive diagnostic test for diagnosing and monitoring large vessel vasculitides and is recommended nowadays as the first complementary method to clinical examination.
- Imaging is a reasonable alternative or at least a good complement to temporal artery biopsy in the case of suspected giant cell arteritis.
- Today's EULAR guidelines recommend CCDS as the preferred diagnostic test in suspected giant cell arteritis, with MRI as an equivalent alternative in the case of inconclusive results, and MRI as the first choice in suspected Takayasu's arteritis.

Citation Format

- Guggenberger K, Bley T. Imaging in Large Vessel Vasculitides. *Fortschr Röntgenstr* 2019; 191: 1083–1090

Introduction

This review outlines today's imaging options in the diagnosis and therapy monitoring of large vessel vasculitides (LVV), a group of primary vasculitides, characterized by autoimmune mediated granulomatous inflammatory processes of large and medium-sized blood vessels, with the aorta and its major branches as predilection sites [1]. The two major forms of large vessel vasculitis are giant cell (temporal) arteritis (GCA) and Takayasu's arteritis (TA) [2].

Large vessel vasculitides

GCA and TA differ mainly in terms of clinical symptoms, anatomical location of the affected vessels and involvement pattern, as well as epidemiological conditions. While GCA is a disease of the elderly, often associated with polymyalgia rheumatica, with a disease onset at usually 50 years and older, TA mostly affects younger people under the age of 50 years [1, 3].

In both entities the aorta and its major branches are affected. While the supra-aortic vessels such as the subclavian, carotid, axillary, and the superficial cranial arteries, in particular the superficial temporal and occipital artery show typical signs of inflammation in GCA, typically with a segmental involvement pattern [4–6], TA predominantly affects the aortic arch and its major branches from the carotid to the external iliac artery, including the pulmonary artery [1, 7].

LVV may be associated with considerable morbidity and mortality. Early diagnosis and adequate therapy are essential for preventing these complications. The seriousness of the most common complications in GCA and TA is particularly due to the involved vessels' vicinity and relevance in terms of blood supply to the brain and its associated structures. Cerebrovascular involvement and damage is a well-known complication in TA and is controversially discussed in GCA [8–10]. Irreversible vision loss as a result of anterior ischemic optic neuropathy (AION) in the

case of GCA, stenosis and occlusion of large arteries with the consequence of ischemic (brain) injuries as well as aortic aneurysms and dissections in the case of TA belong to the most severe sequelae of vasculitic vessel changes [11–13].

Diagnosis of large vessel vasculitides

Identifying patients with LVV might be a challenge as they often present with nonspecific clinical symptoms and systemic inflammatory constellation of laboratory values. To date, the classification criteria for GCA of the American College of Rheumatology (ACR) include various clinical aspects and histopathological findings of the superficial temporal artery, but no imaging features [14, 15]. Temporal artery biopsy is still considered the "gold standard" in diagnosing the cranial form of GCA [14, 16, 17].

Due to rapid technological progress and its low invasiveness yet good diagnostic reliability, imaging has gained in importance in the diagnosis and monitoring of LVV. Today, imaging is the preferred complementary method to clinical examination as a reliable noninvasive alternative to temporal artery biopsy [18].

Imaging modalities and imaging findings in LVV

The most common imaging modalities in the context of LVV are color-coded duplex sonography (CCDS), computed tomography/CT angiography (CTA), magnetic-resonance imaging/angiography (MRI/MRA), and ^{18}F -fluorodeoxyglucose positron emission tomography (FDG-PET) [19, 20]. ► **Table 1** summarizes the imaging modalities used in the context of LVV and the respective typical imaging findings. For further technical details, we refer to the recently published EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice [18].

► **Table 1** Imaging modalities in large vessel vasculitides, their advantages and disadvantages and typical findings [42].

► **Tab. 1** Bildgebende Diagnostik der Großgefäßvaskulitiden, ihre Vorteile, Nachteile und typische Bildbefunde.

imaging modality	advantages	disadvantages	typical findings in large vessel vasculitides
CCDS GCA: sensitivity 77 %, specificity 96 % with clinical diagnosis of GCA as the reference standard [43]	<ul style="list-style-type: none"> > good availability > fast, reliable, non-invasive > high resolution > no radiation > no nephrotoxic contrast agents > low costs > dynamic examination (flow measurement) 	<ul style="list-style-type: none"> > operator-dependent > limited by anatomical location (especially thoracic aorta and proximal supra-aortic branches) > limited information on inflammatory activity 	<ul style="list-style-type: none"> > hypoechogenic, non-compressible "halo" sign > facultative alterations of the flow velocity profile
CT/CTA GCA: sensitivity 73 %, specificity 78 % with clinical diagnosis as the reference standard [44] TA: sensitivity 100 %, specificity 100 % with conventional angiography as the reference standard [45]	<ul style="list-style-type: none"> > good availability > fast, reliable, non-invasive > high resolution > wide scan range > relatively high specificity, good differential diagnosis > assessment of morphologic changes and inflammatory activity, especially the vessels' lumen and wall and the surrounding tissue 	<ul style="list-style-type: none"> > radiation exposure > nephrotoxic contrast agents 	<ul style="list-style-type: none"> > mural thickening and enhancement, late contrast uptake > vascular stenosis/occlusion/ectasia > surrounding edema/tissue reaction
MRI/MRA GCA: sensitivity 73 %, specificity 88 % with clinical diagnosis of GCA as the reference standard [43] TA: sensitivity 100 %, specificity 100 % with conventional angiography as the reference standard [46]	<ul style="list-style-type: none"> > high resolution > wide scan range > technical flexibility > functional/dynamic imaging > high sensitivity and specificity, good differential diagnosis > intracranial, extracranial and large vessel assessment possible > assessment of morphologic changes and inflammatory 	<ul style="list-style-type: none"> > limited availability > time-consuming > dependent on patients' compliance > expensive > no standardized reading 	<ul style="list-style-type: none"> > mural thickening and enhancement > vascular stenosis/occlusion/ectasia > surrounding edema/tissue reaction > sequelae, e. g. infarction, necrosis, bleeding
FDG-PET extracranial GCA: sensitivity 67 – 77 %, specificity 66 – 100 % with temporal artery biopsy/clinical diagnosis as the reference standard [44, 47]	<ul style="list-style-type: none"> > high resolution > wide scan range > assessment of morphologic changes and inflammatory activity, especially the vessels' lumen and wall and the surrounding tissue 	<ul style="list-style-type: none"> > limited availability > expensive > radiation exposure > relatively low sensitivity 	<ul style="list-style-type: none"> > mural thickening and tracer uptake > vascular stenosis/occlusion/ectasia > surrounding edema/tissue reaction
conventional angiography	<ul style="list-style-type: none"> > high sensitivity in luminal changes, especially in small vasculature 	<ul style="list-style-type: none"> > limited availability > expensive > radiation exposure > nephrotoxic contrast agents > relatively low sensitivity > operator-dependent > no information on vessels' wall and surrounding tissue 	<ul style="list-style-type: none"> > vascular stenosis/occlusion/ectasia

CCDS

With CCDS, the vessel's lumen as well as the vascular wall anatomy and the directly surrounding tissue may be assessed. For visualization of small arteries, particularly the superficial cranial arteries, a high-frequency linear transducer with a B-mode frequency of at least 10 MHz, optimally ≥ 15 MHz should be used [18, 21]. For sonographic imaging of the extracranial supra-aortic and extremity arteries, linear probes with a minimum frequency of 5 MHz, optimally > 8 MHz (7 – 15 MHz [18]) are preferably applied. For the assessment of large vessels, especially the abdomi-

nal aorta and its visceral branches as well as the iliac arteries, a curved array probe with a lower frequency (usually 3.5 – 5 MHz) is usually required.

Image resolution of 0.1 mm for superficial arteries can be achieved with modern ultrasound transducers [21]. A hypoechogenic, non-compressible halo sign around inflamed vessels is the typical finding in vasculitides, in the case of giant cell arteritis especially around the superficial temporal artery [22]. Sometimes, alternations of the Doppler spectrum, as well as stenosis or even occlusion of the affected vessel's lumen may occur. Atherosclerotic plaques, in contrast to vasculitic stenosis, usually

have a more heterogeneous, eccentric and irregular nature. Measurement of the intima-media thickness was demonstrated to have a relatively high predictive value and can reliably distinguish vasculitic from normal arteries in suspected GCA [23]. Contrast-enhanced ultrasound may depict further information about the vessel wall. Contrast uptake of the vessel wall can visualize hyperemia and hypervascularization, typical features of an ongoing inflammatory process [24].

MRI/MRA

In both GCA and TA, the involvement patterns are variable and may include the coronary, carotid, external iliac, as well as the superficial cranial and the intracranial arteries. Therefore, imaging should include the potentially affected vasculature to capture the entire disease extent. MR imaging has a relatively wide scan range and is suitable for the assessment of the vessel's lumen and wall of large body vessels, and extracranial superficial cranial arteries, particularly the superficial temporal and occipital arteries [25, 26]. Furthermore, intracranial arteries as well as the surrounding tissue and any complications can be assessed simultaneously.

MR vessel wall imaging requires suppression of the signal arising from the luminal blood or from other surrounding structures, such as the brain parenchyma or cerebrospinal fluid in the case of intracranial arteries in order to clearly differentiate the vessel wall [27]. A contrast-enhanced, fat-suppressed, high-resolution black blood T1-weighted spin echo sequence is the most valuable sequence for detecting mural inflammatory changes in superficial cranial arteries in GCA.

MR angiography, especially TOF (time-of-flight) angiography in the case of assessment of the intracranial arteries and contrast-enhanced time-resolved TWIST (time-resolved angiography with interleaved stochastic trajectories) angiography in the case of assessment of the large body vessels, are helpful to evaluate the lumen diameter, detect any vessel stenosis or occlusion and blood flow alterations. However, they are not suitable for the visualization of specific vasculitic changes as they do not delineate the vessel walls.

Navigated fat-suppressed T1w-3D black-blood MRI with peripheral pulse unit triggering has been demonstrated to be a reliable tool in the diagnosis of thoracic LVV [28].

Unenhanced T1-weighted, T2-weighted or diffusion-weighted imaging might add important anatomical and functional information and may be helpful in detecting vasculitic complications, such as infarctions or hemorrhage.

Characteristic MRI findings of vasculitis comprise direct and indirect signs [29]. Direct signs of vessel inflammation include mural thickening greater 600 µm and contrast enhancement of the affected vessel [26]. Stenosis or occlusion of the affected vessels may be present. Indirect signs of vasculitides, indicating already incurred complications, include non-arteriosclerotic vascular stenosis and, in the case of brain-supplying arteries, cerebral ischemic infarction or perfusion deficit and intraparenchymatous or subarachnoid hemorrhage [29]. Vascular stenosis caused by inflammation is characterized by circular contrast enhancement and narrowing of the luminal diameter, in contrast to eccentric plaque and stenosis in case of arteriosclerotic changes [29, 30].

CT/CTA

CT is a widely available and fast cross-sectional imaging method able to capture vessels from the skull to the lower limbs in one scan. CT-angiography combined with a parenchymal, venous or portal venous contrast phase allows assessment of the vessels' lumen in terms of caliber irregularities or stenosis, the vessels' wall in terms of thickening and contrast enhancement, and assessment of the surrounding tissue [18]. CT is suitable for detecting structural lesions and wall inflammation with a higher resolution and shorter procedural time than MRI, however it entails radiation exposure [31]. Vasculitic vessel wall lesions are usually smoother and more homogeneous than arteriosclerotic lesions. Calcifications are not typical.

FDG-PET

¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) provides functional information in terms of metabolic activity and is rather known for its significance in oncology. FDG-PET allows whole-body imaging, thus the assessment of all vascular territories, in one single examination. FDG-PET may deliver valuable information for diagnosis, extent assessment, disease activity and therapy response evaluation. However, it does not clearly delineate the vessel wall. Increased FDG-uptake in the vessel wall indicates hypermetabolism, a typical feature of vasculitis on PET, thus depicting disease activity. In general, visual FDG-uptake of the vessel wall that is higher than the tracer uptake in the liver suggests vasculitic changes in the context of large vessel vasculitides [32]. A characteristic finding in GCA is a linear or segmental pattern of tracer uptake in the aorta and its main branches [33]. However, trace uptake is nonspecific and, as in other imaging methods, differentiation between vasculitic and arteriosclerotic lesions might be a challenge [34].

Conventional angiography

Particularly due to its invasiveness, conventional angiography has lost importance in the context of LVV over the past years and has been replaced mostly by less invasive imaging techniques [18, 35]. Conventional angiography in general is an invasive imaging method allowing very sensitive assessment of the lumen of large and small vessels in terms of stenosis and occlusion, with the additional option of therapeutic intervention in the same procedure. Vasculitic vessel changes of large and medium-sized vessels, in particular vascular stenosis and occlusion or aneurysms sometimes require surgical interventions, especially in symptomatic disease refractory to immunosuppressive medical therapy. Therapeutic options include open surgery or endovascular intervention, with percutaneous transluminal angioplasty, stent insertion, and stent graft placement as possible options [36]. Considering the size of the affected vessels, endovascular therapy is mainly suitable for the treatment of TA lesions, especially of the aorta and the supraaortic branches, the coronary and renal arteries [36]. Endovascular treatment in GCA is rare and is mainly applied in the case of extracranial vessel involvement, in particular balloon angioplasty in the case of stenosis or occlusion of upper or lower limb arteries [37, 38]. There are only a few cases described in the literature

► **Fig. 1** Typical imaging findings in giant cell arteritis: A hypoechoic, non-compressible “halo” sign around the left superficial temporal artery (a, b, arrows), combined with a pathological flow pattern on CCDS (c, arrow), FDG-uptake on PET (d, arrow) and a thickened, enhancing vessel wall on MRI (e, arrow).

► **Abb. 1** Typische Bildbefunde einer Arteriitis temporalis: Echoarmes, nicht kompressibles Halo-Zeichen um die A. temporalis superficialis links (a, b, Pfeile), kombiniert mit einem pathologischen Flussprofil in der Dopplersonografie (c, Pfeil), FDG-Aufnahme im PET/CT (d, Pfeil) und einer entzündlichen Wandverdickung und Kontrastmittelaufnahme in der MRT (e, Pfeil).

in which endovascular stenting of the internal carotid artery and the vertebral artery was attempted [39–41]. However, the specificity of conventional angiography regarding the diagnosis of vasculitic vessel changes is limited, as it does not depict the vessel walls or surrounding tissue but just the intraluminal flow. Typically, vasculitic stenoses display smooth tapering of the affected segment compared to more clearly delineated arteriosclerotic stenoses (► Fig. 1, 2, ► Table 1).

EULAR recommendations concerning the use of imaging in the diagnosis and monitoring of patients with large vessel vasculitides

EULAR (The European League Against Rheumatism) has recently published its first recommendations on the role of imaging in the diagnosis and monitoring of patients with suspected large vessel

vasculitides. These recommendations are mainly based on a systematic literature review [43], intended to guide primary, secondary and tertiary care physicians, such as neurologists, ophthalmologists and rheumatologists through diagnosis and monitoring in regard to the application of imaging modalities [18]. Considering the severity of possible complications, early initiation of adequate therapy should be the first priority in the management of large vessel vasculitides. Presuming expertise, adequate equipment, operational procedures and settings, an early imaging examination is considered the preferred complement to clinical criteria in patients with suspected large vessel vasculitides. Preferably, imaging should take place before or as early as possible after the initiation of therapy, as the sensitivity is significantly reduced within a few days of treatment with glucocorticoids [48–51]. However, if adequate imaging is not readily available or if the imaging tests are inconclusive, other diagnostic tests should be conducted to clarify the suspected diagnosis or, in the case of

► **Fig. 2** Typical imaging findings in Takayasu arteritis: Circular wall thickening of both common carotid arteries on MRI and CCDS (**a, d** arrows), a hypoechoic, non-compressible "halo" sign around the axillary arteries (**b, c**, arrows) with a flow acceleration up to 200 cm/s on CCDS (**c**, arrow) as well as trace uptake of the aorta's wall (**e**, arrows) and both axillary arteries (**f**, arrows) on PET.

► **Abb. 2** Typische Bildbefunde einer Takayasu-Arteriitis: Zirkuläre Wandverdickung der A. carotis communis beidseits in MRT und Dopplersonografie (**a, d**, Pfeile), ein echoarmes, nicht kompressibles Halo-Zeichen um die A. axillares (**b, c**, Pfeile) mit einer Flussbeschleunigung auf bis etwa 200 cm/s in der Dopplersonografie (**c**, Pfeil) sowie Trace-Aufnahme der Aortenwand (**e**, Pfeile) und der A. axillaris beidseits in der PET/CT (**f**, Pfeil).

clinically obvious cases, treatment should be started in spite of an incomplete diagnostic process.

Giant cell arteritis

In the case of suspected predominantly cranial GCA, color-coded duplex sonography (CCDS) of the temporal or/and axillary arteries is recommended as the preferred imaging modality, especially because of its widespread and fast availability, good reliability, and absence of procedural risks such as radiation and cost-efficiency. If CCDS is inconclusive or not available, an alternative is high-resolution MRI. The sensitivity and specificity of CCDS and high-resolution MRI in detecting mural inflammation signs in giant cell arteritis are of comparable value [43, 52].

In the case of a positive imaging test and high clinical probability, GCA may be diagnosed without any further testing. In the case of a negative imaging test and low clinical suspicion, GCA may be considered unlikely [18]. In the case of uncertainty after clinical examination and imaging, further steps need to be taken to confirm or exclude GCA. CT and PET are not suitable for assessing inflammation of intracranial arteries. However, CCDS, PET, MRI or CT may be used to assess inflammatory wall and/or luminal changes in extracranial arteries in the framework of GCA.

Temporal artery biopsy is not supposed to be discarded as a diagnostic procedure in GCA in favor of imaging by the new EULAR recommendations. Instead, imaging should be preferred over biopsy as a diagnostic procedure for its low invasiveness, rapid availability of imaging results and its superior evaluation of disease extent and identification of other involved arteries in further locations. This is of importance, since GCA is a systemic disease

and most often affects more than a single vessel territory. However, under circumstances in which adequate imaging and expertise are not available, temporal artery biopsy is indicated to confirm clinically suspected GCA. Imaging is redundant, provided that temporal artery biopsy has already been conducted and is positive [18]. A negative biopsy result does not rule out GCA as there might still be unaffected segments of the temporal artery in active vasculitis. In the case of a negative or questionable biopsy, imaging might provide additional information.

Takayasu's arteritis

In suspected TA, MRI is recommended as the preferred diagnostic test if available to investigate luminal changes and mural inflammation. Alternatively, PET, CT and/or CCDS may be used for the assessment of inflammation processes or luminal changes in patients with TA. However, the value of CCDS in assessing the aorta and some of its branches is limited due to their anatomical location [18].

For long-term monitoring of large vessel vasculitides as well as the assessment of complications and structural damage, MRI/MRA, CTA and/or CCDS may be used. The modality and frequency of repeat scanning should be adjusted to the individual circumstances. However, routine imaging is not provided for patients in clinical and biochemical remission. Conventional angiography is not recommended anymore in the diagnosis and monitoring of large vessel vasculitides [18, 35].

Discussion

The major limitation of imaging in large vessel vasculitides is the significant decrease in the sensitivity of CCDS and MRI after treatment initiation with glucocorticoids [51]. It is reported that the sensitivity of MRI decreases significantly within five days after therapy initiation [53], and the halo sign in CCDS disappears about 14–21 days after initiation of glucocorticoid treatment [54]. However, within several days after treatment initiation, diagnosis through imaging, no matter which modality, may be difficult in some cases [55].

In contrast, temporal artery biopsy seems to be valuable up to 4 weeks after treatment initiation [56].

Furthermore, each modality has its specific constraints. CCDS is an operator-dependent diagnostic test, based on the operator's subjective evaluation of findings and the lack of reproducibility. The availability of MRI is restricted, its costs are relatively high and the required imaging times may be rather long. CT, PET/CT and conventional angiography are associated with radiation exposure and use of i. v. contrast agents. Conventional angiography has a high sensitivity in detecting vessel stenosis or occlusion with the option of endovascular treatment if needed. However, besides its invasiveness, its comparably low specificity regarding the underlying cause of luminal change is a limiting factor. Conventional angiography only depicts luminal changes occurring in advanced vasculitic disease stages, and it cannot adequately capture early signs of vasculitic disease, in particular vessel wall changes where the luminal diameter is still preserved.

The diagnostic value of the two first-choice modalities in GCA and TA, i. e., CCDS and MRI, is comparable (pooled sensitivity of MRI: 73 %; specificity: 88 %) [43]. There is not much data on the diagnostic value of CT/CTA in the diagnosis of LVV, a small study indicates a sensitivity of 73 % and a specificity of 78 % for CTA in diagnosing GCA [31].

Summary

As a result of ongoing technological progress, imaging has gained great importance in the diagnosis and therapy monitoring of large vessel vasculitides. Due to its low invasiveness and high diagnostic reliability, imaging is a reasonable alternative and/or good complement to temporal artery biopsy. There are a variety of possible imaging modalities in the context of large vessel vasculitides, and sometimes different imaging tests can supply complementary information. Today's EULAR guidelines concerning the diagnosis of large vessel vasculitides recommend an imaging test as the first complementary method to clinical examination with CCDS as the preferred imaging modality in suspected GCA, MRI as an equivalent alternative in the case of inconclusive results, and MRI as the first choice in suspected TA.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- [1] Tracy A, Cardy CM, Carruthers D. Large vessel vasculitides. *Medicine* 2018; 46: 112–117
- [2] Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013; 65: 1–11
- [3] Versari A, Pipitone N, Casali M et al. Use of imaging techniques in large vessel vasculitis and related conditions. *Q J Nucl Med Mol Imaging* 2018; 62: 34–39
- [4] Bley TA, Weiben O, Uhl M et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. *Arthritis Rheum* 2005; 52: 2470–2477
- [5] Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis: a pathological study to show the pattern of arterial involvement. *Arch Neurol* 1972; 27: 378–391
- [6] Klein RG, Campbell RJ, Hunder GG et al. Skip lesions in temporal arteritis. *Mayo Clin Proc* 1976; 51: 504–510
- [7] Chung JW, Kim HC, Kim SJ et al. Patterns of aortic involvement in Takayasu arteritis and its clinical implications: evaluation with spiral computed tomography angiography. *J Vasc Surg* 2007; 45: 906–914
- [8] Siemonsen S, Brekenfeld C, Holst B et al. 3T MRI reveals extra- and intracranial involvement in giant cell arteritis. *Am J Neuroradiol* 2015; 36: 91–97
- [9] Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis: a pathological study to show the pattern of arterial involvement. *Arch Neurol* 1972; 27: 378–391
- [10] Salvarani C, Giannini C, Miller DV et al. Giant cell arteritis: involvement of intracranial arteries. *Arthritis Rheum* 2006; 55: 985–989
- [11] Salvarani C, Cimino L, Macchioni P et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. *Arthritis Rheum* 2005; 53: 293–297
- [12] Salvarani C, Pipitone N, Versari A et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. *Nat Rev Rheumatol* 2012; 8: 509–521
- [13] Direskeneli H. Clinical assessment in Takayasu's arteritis: major challenges and controversies. *Clin Exp Rheumatol* 2017; 35: 189–193
- [14] Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum* 1990; 33: 1122–1128
- [15] Arend WP, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990; 33: 1129–1134
- [16] Hall S, Persellin S, Lie JT et al. The therapeutic impact of temporal artery biopsy. *Lancet* 1983; 2: 1217–1220
- [17] Mukhtyar C, Guillemin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis* 2009; 68: 318–323
- [18] Dejaco C, Ramiro S, Duftner C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. *Ann Rheum Dis* 2018; 77: 636–643
- [19] Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. *Curr Opin Rheumatol* 2009; 21: 19–28
- [20] Cimmino MA, Camellino D. Large vessel vasculitis: Which imaging method? *Swiss Med Wkly* 2017; 147: w14405
- [21] Muratore F, Pipitone N, Salvarani C et al. Imaging of vasculitis: State of the art. *Best Pract Res Clin Rheumatol* 2016; 30: 688–706
- [22] Chrysidis S, Duftner C, Dejaco C et al. Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. *RMD open* 2017

- [23] Schäfer VS, Juche A, Ramiro S et al. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. *Rheumatology (Oxford)* 2017; 56: 1479–1483. doi:http://dx.doi.org/10.1093/rheumatology/kex143
- [24] Germanò G, Macchioni P, Possemato N et al. Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. *Arthritis Care Res (Hoboken)* 2017; 69: 143–149. doi:http://dx.doi.org/10.1002/acr.22906
- [25] Bley TA, Uhl M, Carew J et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. *Am J Neuroradiol* 2007; 28: 1722–1727
- [26] Bley TA, Wieben O, Uhl M et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. *Am J Roentgenol* 2005; 184: 283–287
- [27] Mandell DM, Mossa-Basha M, Qiao Y et al. Intracranial vessel wall MRI: principles and expert consensus recommendations of the American Society of Neuroradiology. *Am J Neuroradiol* 2017; 38: 218–229
- [28] Treitl KM, Maurus S, Sommer NN et al. 3D-black-blood 3T-MRI for the diagnosis of thoracic large vessel vasculitis: A feasibility study. *Eur Radiol* 2017; 27: 2119–2128. doi:10.1007/s00330-016-4525-x
- [29] Küker W. Imaging of cerebral vasculitis. *Int J Stroke* 2007; 2: 184–190
- [30] Mossa-Basha M, Hwang WD, De Havenon A et al. Multicontrast high-resolution vessel wall magnetic resonance imaging and its value in differentiating intracranial vasculopathic processes. *Stroke* 2015; 46: 1567–1573
- [31] Lariviere D, Benali K, Coustet B et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: A real-life prospective study. *Medicine* 2016; 95: e4146
- [32] Stellingwerff MD, Brouwer E, Lensen KJ et al. Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization. *Medicine (Baltimore)* 2015; 94: e1542. doi:http://dx.doi.org/10.1097/MD.0000000000001542
- [33] Besson FL, Parienti JJ, Bienvenu B et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2011; 38: 1764–1772. doi:http://dx.doi.org/10.1007/s00259-011-1830-0
- [34] Puppo C, Massollo M, Paparo F et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. *BioMed Res Int* 2014; 2014: 574248. doi:http://dx.doi.org/10.1155/2014/574248
- [35] Direskeneli H. Clinical assessment in Takayasu's arteritis: major challenges and controversies. *Clin Exp Rheumatol* 2017; 35: 189–193
- [36] Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. *Rheumatology (Oxford)* 2014; 53: 793–801. doi:10.1093/rheumatology/ket320. Epub 2013 Oct 4
- [37] McLachlan RHP, Lennox AF, Varcoe RL et al. Endovascular treatment of critical lower limb ischemia caused by giant cell arteritis. *J Vasc Surg Cases Innov Tech* 2019; 5: 31–34. Published online 2019 Jan 7. doi:10.1016/j.jvscit.2018.09.008
- [38] Both M, Aries PM, Müller-Hülsbeck S et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. *Ann Rheum Dis* 2006; 65: 1124–1130
- [39] Chausson N, Olindo S, Signate A et al. Bilateral intracerebral angioplasty in a patient with stroke caused by giant cell arteritis. *Rev Neurol (Paris)* 2010; 166: 328–332
- [40] Guerrero AM, Sierra-Hidalgo F, Calleja P et al. Intracranial internal carotid artery angioplasty and stenting in giant cell arteritis. *J Neuroimaging* 2015; 25: 307–309
- [41] Dementovych N, Mishra R, Shah QA. Angioplasty and stent placement for complete occlusion of the vertebral artery secondary to giant cell arteritis. *J Neurointerv Surg* 2012; 4: 110–113
- [42] Berger CT, Sommer G, Aschwanden M et al. The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis. *Swiss Med Wkly* 2018; 148: w14661. doi:smw.2018.14661. eCollection 2018 Aug 13
- [43] Duftner C, DeJaco C, Sepriano A et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. *RMD Open* 2018; 4: e000612. doi:10.1136/rmdopen-2017-000612. eCollection 2018
- [44] Lariviere D, Benali K, Coustet B et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: A real-life prospective study. *Medicine* 2016; 95: e4146
- [45] Yamada I, Nakagawa T, Himeno Y et al. Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. *Radiology* 1998; 209: 103–109
- [46] Yamada I, Nakagawa T, Himeno Y et al. Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. *J Magn Reson Imaging* 2000; 11: 481–487
- [47] Blockmans D, Stroobants S, Maes A et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. *Am J Med* 2000; 108: 246–249
- [48] Luqmani R, Lee E, Singh S et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. *Health Technol Assess* 2016; 20: 1–238
- [49] Schmidt WA, Kraft HE, Vorpahl K et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. *N Engl J Med* 1997; 337: 1336–1342
- [50] Karahaliou M, Vaiopoulos G, Papaspyrou S et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. *Arthritis Res Ther* 2006; 8: R116
- [51] Hauenstein C, Reinhard M, Geiger J et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. *Rheumatology* 2012; 51: 1999–2003
- [52] Bley TA, Reinhard M, Hauenstein C et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. *Arthritis Rheum* 2008; 58: 2574–2578
- [53] Klink T, Geiger J, Both M et al. Diagnostic Accuracy of MR Imaging of Superficial Cranial Arteries in Initial Diagnosis – Results from a Multicenter Trial. *Radiology* 2014; 273: 844–852. doi:10.1148/radiol.14140056. Epub 2014 Aug 6
- [54] Schmidt WA. Role of ultrasound in the understanding and management of vasculitis. *Ther Adv Musculoskelet Dis* 2014; 6: 39–47
- [55] Hauenstein C, Reinhard M, Geiger J et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. *Rheumatology (Oxford)* 2012; 51: 1999–2003
- [56] Narvaez J, Bernad B, Roig-Vilaseca D et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. *Semin Arthritis Rheum* 2007; 37: 13–19